Install
Where the world charts, chats and trades markets. We're a supercharged super-charting platform and social network for traders and investors. Free to sign up.
- 189,656articles · 180d
- 1+ day agolatest article
- Mar 16, 2026earliest in window
- 94%with images · 53 videos
- 128avg words
- business 97,520
- stock 90,466
- markets 84,446
- stocks 64,228
- stock market 37,747
- companies 36,141
- investing 35,987
- finance 35,904
- business news 33,752
- stock market news 26,060
- investment 25,314
- tmt newswire 24,231
- globenewswire 22,213
- financial 21,502
- investment advice 20,710
- online trading 19,285
- technology 18,885
- online investment 17,716
- economy 16,866
- online stock trading 15,660
- Economy, Business & Finance 181,940
- Finance & Business 177,455
- News 98,192
- Finance 53,126
- Business & Industrial 22,676
- Industrial 3,952
- Health & Wellness 3,083
- Computers & Electronics 2,213
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
MANE: VDPHL01 Phase 2 data in women showed strong efficacy, rapid onset, and favorable safety — TradingView News
1+ mon, 4+ week ago (92+ words) MANE: VDPHL01 Phase 2 data in women showed strong efficacy, rapid onset, and favorable safety TradingView MANE: VDPHL01 Phase 2 data in women showed strong efficacy, rapid onset, and favorable safety Phase 2 open-label data for VDPHL01 in women with pattern hair loss showed robust hair…...
ABSI: ABS-201 advances in phase II trials, targeting major unmet needs in hair loss and endometriosis
3+ mon, 3+ day ago (84+ words) TradingView ABSI: ABS-201 advances in phase II trials, targeting major unmet needs in hair loss and endometriosis AI-driven drug design has enabled rapid, cost-effective development of ABS-201, now in phase II trials for androgenic alopecia and soon for endometriosis. Preclinical…...
Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant
4+ mon, 3+ week ago (525+ words) Positive Safety Profile Supports Chronic Use Male AGA is a chronic progressive condition that often begins early and requires years of treatment. For that reason, long-term tolerability is essential. Across 12 months of treatment, Clascoterone maintained a safety and tolerability profile…...
Cosmo Pharma's male hair loss treatment shows sustained hair growth in year‑long study
4+ mon, 3+ week ago (35+ words) TradingView — Track All Markets Cosmo Pharma's male hair loss treatment shows sustained hair growth in year‑long study More news from Reuters...